EpiVax Enters its Next Chapter with SV Health Investors
EpiVax today announced its acquisition by SV Health Investors (SVHI), a healthcare and life sciences-focused private investment firm. This milestone marks an exciting new chapter and will accelerate further development of EpiVax’s scientific capabilities, methodologies, and strategic direction.
For more than 25 years, EpiVax has led the field of immunogenicity risk assessment, helping biologics developers make informed, high-stakes pipeline decisions. What began as a focused effort to better understand and predict immune responses has grown into a comprehensive suite of computational and experimental solutions supporting programs from early discovery through clinical development.
Founded by Annie De Groot, MD, and Bill Martin, EpiVax has become a pioneer in computational immunology, defined by scientific rigor and innovation. Their leadership has shaped not only the company, but also the broader field of immunogenicity assessment.
“This partnership marks an important next chapter for EpiVax and reflects SV Health Investors’ confidence in our leadership team, differentiated capabilities, and scientific expertise,” said Annie De Groot, MD. “We are proud of EpiVax’s reputation as an industry leader, and confident that SVHI is the right partner to take the company forward.”
SVHI brings decades of experience building and scaling healthcare and life sciences companies, particularly in outsourced pharma services. Their partnership approach, combined with strategic resources and a broad industry network, positions them to support EpiVax’s next phase of growth.
Rich-Henry Schabowsky, PhD, JD, EpiVax CEO, added, “The collaboration with SVHI will strengthen EpiVax’s position as leaders in immunogenicity risk assessment, accelerating our strategic growth and science-driven innovation, and enhancing our ability to support our global pharma and biotech partners in improving risk and resource management and in more efficiently developing regulatory-ready strategies.”
This moment reflects both continuity and momentum. Having recently added immunogenicity expert and current CSO, Vibha Jawa, PhD, to the team, EpiVax will continue expanding its capabilities, including upcoming advances in computational tools, diversified cell-based assays, and consulting services. The focus remains on equipping partners with the insights needed to make confident, risk-based decisions across the development lifecycle, while expanding impact and collaboration across the pharmaceutical and biotech landscape.
As part of this transition, EpiVax’s founders will continue to support the organization in consulting roles while pursuing new endeavors. After 28 years leading EpiVax, Annie De Groot will launch a new effort at EVA Therapeutics, focused on equitable vaccine access and the development of immune-modulating therapies.
The EpiVax team thanks Annie and Bill for their visionary leadership, their commitment to “fearless science,” and the strong foundation they have built. With SVHI as a partner, EpiVax is well positioned to enter its next phase— “EpiVax 2.0”—with confidence and momentum.
